GALT
Galectin Therapeutics Inc.
Biotechnology
Market Cap$136M
5Y Perf.-30.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GALT vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
GALT vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GALT | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $136M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-37M | $-168M |
| Total Debt | $106M | $22M |
| Cash & Equiv. | $15M | $194M |
GALT vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GALT
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Galectin Therapeuti… (GALT) | 100 | 69.6 | -30.4% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GALT vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GALT and DBVT are tied at the top with 3 categories each — the right choice depends on your priorities. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GALT
Galectin Therapeutics Inc.
The Income Pick
GALT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.70, yield 0.1%
- EPS growth -2.7%
- 67.4% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs GALT's -29.7%
- +110.4% vs GALT's +34.4%
- -89.0% ROA vs GALT's -290.0%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GALT | -59.9% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs GALT's -29.7% |
| Stability / Safety | GALT | Beta 0.70 vs DBVT's 1.26 |
| Dividends | GALT | 0.1% yield; the other pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs GALT's +34.4% |
| Efficiency (ROA) | DBVT | -89.0% ROA vs GALT's -290.0% |
GALT vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGGALT
GALTGalectin Therapeutics…
1leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs GALTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
GALT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
GALT and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$31M | -$112M |
| Net IncomeAfter-tax profit | -$37M | -$168M |
| Free Cash FlowCash after capex | -$31M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +27.8% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
GALT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $136M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $227M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -2.78x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
GALT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
DBVT leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs GALT's 1/9, reflecting mixed financial health.
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | -2.9% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $91M | -$172M |
| Cash & Equiv.Liquid assets | $15M | $194M |
| Total DebtShort + long-term debt | $106M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -4.24x | -189.82x |
DBVT leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GALT five years ago would be worth $5,275 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs GALT's +34.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs GALT's 3.9% — a key indicator of consistent wealth creation.
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -47.9% | +4.9% |
| 1-Year ReturnPast 12 months | +34.4% | +110.4% |
| 3-Year ReturnCumulative with dividends | +12.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | -47.2% | -69.1% |
| 10-Year ReturnCumulative with dividends | +67.4% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +3.9% | +6.2% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GALT and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
GALT is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs GALT's 29.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.26x |
| 52-Week HighHighest price in past year | $7.13 | $26.18 |
| 52-Week LowLowest price in past year | $1.21 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +29.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 347K | 252K |
Evenly matched — GALT and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GALT as "Buy" and DBVT as "Buy". Consensus price targets imply 421.3% upside for GALT (target: $11) vs 131.8% for DBVT (target: $46).
| Metric | GALTGalectin Therapeu… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.00 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.00 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GALT leads in 1 (Valuation Metrics). 1 tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
GALT vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GALT or DBVT a better buy right now?
Analysts rate Galectin Therapeutics Inc.
(GALT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GALT or DBVT?
Over the past 5 years, Galectin Therapeutics Inc.
(GALT) delivered a total return of -47. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: GALT returned +67. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GALT or DBVT?
By beta (market sensitivity over 5 years), Galectin Therapeutics Inc.
(GALT) is the lower-risk stock at 0. 70β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 79% more volatile than GALT relative to the S&P 500.
04Which is growing faster — GALT or DBVT?
On earnings-per-share growth, the picture is similar: Galectin Therapeutics Inc.
grew EPS -2. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GALT or DBVT?
Galectin Therapeutics Inc.
(GALT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GALT leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — GALT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GALT or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GALT or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Galectin Therapeutics Inc.
(GALT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70)). Both have compounded well over 10 years (GALT: +67. 4%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GALT and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.